Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,161 to 1,180 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus. | Pathogens | 2021 | 34578187 | PubTator, text mining | PubMed |
| CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. | Diagnostics (Basel) | 2021 | 34573864 | PubTator, text mining | PubMed |
| CNV Detection from Exome Sequencing Data in Routine Diagnostics of Rare Genetic Disorders: Opportunities and Limitations. | Genes (Basel) | 2021 | 34573409 | PubTator, text mining | PubMed |
| Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy. | Genes (Basel) | 2021 | 34573328 | PubTator, text mining | PubMed |
| Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen. | Brain Sci | 2021 | 34573264 | PubTator, text mining | PubMed |
| Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy. | Brain Sci | 2021 | 34573206 | PubTator, text mining | PubMed |
| The need for evidence-based treatment decisions in spinal muscular atrophy type 0. | Ann Clin Transl Neurol | 2021 | 34546649 | PubTator, text mining | PubMed |
| SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples. | Elife | 2021 | 34542403 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. | Lancet Neurol | 2021 | 34536405 | PubTator, text mining | PubMed |
| Contribution to the Discovery of a Novel Medicine for a Neuromuscular Disease and of other Promising Molecules for the Treatment of Neurodevelopmental and Neurodegenerative Diseases. | Chimia (Aarau) | 2021 | 34523402 | PubTator, text mining | PubMed |
| Deconvolution of multiplexed transcriptional responses to wood smoke particles defines rapid aryl hydrocarbon receptor signaling dynamics. | J Biol Chem | 2021 | 34520756 | PubTator, text mining | PubMed |
| Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. | ACS Nano | 2021 | 34505766 | PubTator, text mining | PubMed |
| Motor Function of Children with SMA1 and SMA2 Depends on the Neck and Trunk Muscle Strength, Deformation of the Spine, and the Range of Motion in the Limb Joints. | Int J Environ Res Public Health | 2021 | 34501722 | PubTator, text mining | PubMed |
| Therapeutics Development for Alagille Syndrome. | Front Pharmacol | 2021 | 34497511 | PubTator, text mining | PubMed |
| Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. | Ann Clin Transl Neurol | 2021 | 34482646 | PubTator, text mining | PubMed |
| Growth patterns in children with spinal muscular atrophy. | Orphanet J Rare Dis | 2021 | 34481516 | PubTator, text mining | PubMed |
| Chromatin-mediated alternative splicing regulates cocaine-reward behavior. | Neuron | 2021 | 34480866 | PubTator, text mining | PubMed |
| Nusinersen Treatment in Adults With Spinal Muscular Atrophy. | Neurol Clin Pract | 2021 | 34476123 | PubTator, text mining | PubMed |
| Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. | BMJ Neurol Open | 2021 | 34466806 | PubTator, text mining | PubMed |
| The infinite possibilities of RNA therapeutics. | J Ind Microbiol Biotechnol | 2021 | 34463324 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=59